Methyl 2-amino-4-(1,3-benzodioxol-5-yl)-1-(3-chloro-2-methylphenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Methyl 2-amino-4-(1,3-benzodioxol-5-yl)-1-(3-chloro-2-methylphenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate
• 英文别名: methyl 2-amino-4-(1,3-benzodioxol-5-yl)-1-(3-chloro-2-methylphenyl)-5-oxo-4,6,7,8-tetrahydroquinoline-3-carboxylate
• 化学式: C₂₅H₂₃ClN₂O₅
• 分子量: 466.9
• InChiKey: SCDDABYMDBUZRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  91.1
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] INHIBITORS OF INFLUENZA VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE LA GRIPPE
  申请人：COCRYSTAL PHARMA INC

  公开号：WO2020112716A1

  公开（公告）日：2020-06-04

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by Formula I, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制流感病毒在生物样本或患者中复制的方法，减少生物样本或患者中流感病毒的数量，以及治疗患者的流感，包括向该生物样本或患者投予由I式代表的化合物或其药学上可接受的盐的安全有效量。一种药物组合物包括这样一种化合物或其药学上可接受的盐的安全有效量，以及药学上可接受的载体、佐剂或溶剂。
• Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
  申请人：COCRYSTAL PHARMA, INC.

  公开号：US11014941B2

  公开（公告）日：2021-05-25

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas I-III, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者体内流感病毒复制、减少生物样本或患者体内流感病毒数量以及治疗患者流感的方法，包括向所述生物样本或患者施用安全有效量的由式I-III中任一项代表的化合物或其药学上可接受的盐。药物组合物包括安全有效量的此类化合物或其药学上可接受的盐，以及药学上可接受的载体、佐剂或载体。
• PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION
  申请人：COCRYSTAL PHARMA, INC.

  公开号：US20200123177A1

  公开（公告）日：2020-04-23

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas I-III, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
• PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION
  申请人：COCRYSTAL PHARMA, INC.

  公开号：US20210121462A1

  公开（公告）日：2021-04-29

  Provided herein are compounds of Formula A, B or C that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.
• INHIBITORS OF INFLUENZA VIRUS REPLICATION
  申请人：COCRYSTAL PHARMA, INC.

  公开号：US20220048897A1

  公开（公告）日：2022-02-17

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by Formula I, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.